University of Groningen

Therapeutic drug monitoring in patients with tuberculosis and concurrent medical problems

Martson, Anne-Grete; Burch, Gena; Ghimire, Samiksha; Alffenaar, Jan-Willem C.; Peloquin, Charles A.

Published in:
Expert Opinion on Drug Metabolism & Toxicology

DOI:
[10.1080/17425255.2021.1836158](https://doi.org/10.1080/17425255.2021.1836158)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2021

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Martson, A-G., Burch, G., Ghimire, S., Alffenaar, J-W. C., & Peloquin, C. A. (2021). Therapeutic drug monitoring in patients with tuberculosis and concurrent medical problems. *Expert Opinion on Drug Metabolism & Toxicology*, 17(1), 23-39. <https://doi.org/10.1080/17425255.2021.1836158>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Therapeutic drug monitoring in patients with tuberculosis and concurrent medical problems

Anne-Grete Märtson, Gena Burch, Samiksha Ghimire, Jan-Willem C. Alffenaar & Charles A. Peloquin

To cite this article: Anne-Grete Märtson, Gena Burch, Samiksha Ghimire, Jan-Willem C. Alffenaar & Charles A. Peloquin (2021) Therapeutic drug monitoring in patients with tuberculosis and concurrent medical problems, Expert Opinion on Drug Metabolism & Toxicology, 17:1, 23-39, DOI: [10.1080/17425255.2021.1836158](https://doi.org/10.1080/17425255.2021.1836158)

To link to this article: <https://doi.org/10.1080/17425255.2021.1836158>

Published online: 08 Nov 2020.

Submit your article to this journal [↗](#)

Article views: 133

View related articles [↗](#)

View Crossmark data [↗](#)

Citing articles: 1 View citing articles [↗](#)

REVIEW

Therapeutic drug monitoring in patients with tuberculosis and concurrent medical problems

Anne-Grete Märtsen ^{a*}, Gena Burch^{b*}, Samiksha Ghimire^a, Jan-Willem C. Alffenaar^{a,c,d} and Charles A. Peloquin^b

^aDepartment of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands;

^bInfectious Disease Pharmacokinetics Laboratory, College of Pharmacy and Emerging Pathogens Institute, University of Florida, Gainesville, FL, USA; ^cDepartment of Pharmacy, Westmead Hospital, Sydney, Australia; ^dSydney Pharmacy School, The University of Sydney, Sydney, New South Wales, Australia; ^eMarie Bashir Institute of Infectious Diseases and Biosecurity, University of Sydney, Sydney, Australia

ABSTRACT

Introduction: Therapeutic drug monitoring (TDM) has been recommended for treatment optimization in tuberculosis (TB) but is only used in certain countries e.g. USA, Germany, the Netherlands, Sweden and Tanzania. Recently, new drugs have emerged and PK studies in TB are continuing, which contributes further evidence for TDM in TB. The aim of this review is to provide an update on drugs used in TB, treatment strategies for these drugs, and TDM to support broader implementation.

Areas covered: This review describes the different drug classes used for TB, multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB), along with their pharmacokinetics, dosing strategies, TDM and sampling strategies. Moreover, the review discusses TDM for patient TB and renal or liver impairment, patients co-infected with HIV or hepatitis, and special patient populations – children and pregnant women.

Expert opinion: TB treatment has a long history of using ‘one size fits all.’ This has contributed to treatment failures, treatment relapses, and the selection of drug-resistant isolates. While challenging in resource-limited circumstances, TDM offers the clinician the opportunity to individualize and optimize treatment early in treatment. This approach may help to refine treatment and thereby reduce adverse effects and poor treatment outcomes. Funding, training, and randomized controlled trials are needed to advance the use of TDM for patients with TB.

ARTICLE HISTORY

Received 17 July 2020

Accepted 5 October 2020

KEYWORDS

Therapeutic drug monitoring; tuberculosis; mdr-TB; pharmacokinetics; pharmacodynamics

1. Introduction

The use of therapeutic drug monitoring (TDM) [1–5] has become an accepted strategy to optimize the management of tuberculosis (TB) and is recommended in the most recent World Health Organization (WHO) and The American Thoracic Society, U.S. Centers for Disease Control and Prevention, European Respiratory Society, Infectious Diseases Society of America (ATS/CDC/ERS/IDSA) Drug-Resistant TB treatment guidelines [6,7]. There are clear benefits to TDM in TB: avoiding toxicity, guiding therapy in special patient populations, assessing concordance to therapy, assessing potential drug interactions, but also prevention of antimicrobial resistance [2,8]. TDM is more used in certain countries, for example, USA, Germany, the Netherlands and Sweden. A recent review on mass spectrometry for TDM of anti-tuberculosis drugs listed the number of published drug assays by country and the most published assays were in India, USA and China [9].

Before starting TDM it is important to identify which drugs are the best candidates for performing TDM. Criteria for TDM include pharmacokinetic (PK) variability and stability, pharmacodynamic (PD) relationships like concentration-related toxicity and a narrow therapeutic window [10]. Furthermore, it is important to know whether and how specific PK/PD targets

are defined for each drug. Traditionally PK/PD targets were based on animal models; however, this has moved on to using hollow fiber infection models, mimicking human pharmacokinetics [11]. With the hollow fiber infection model, it is possible to explore the impact of both PK and PD over a specified time period.

For TDM in TB either specific concentrations C_1 , C_2 , C_6 (concentration at 1 h, 2 h and 6 h after administration, respectively), C_{min} (trough concentration), C_{max} (maximum concentration), or measures of drug exposure like AUC (area under the concentration–time curve, drug exposure over time) and $fAUC$ (the area under the unbound drug concentration–time curve) are used. Limited Sampling Strategies (LSS) have been developed using population pharmacokinetic models, and Monte Carlo simulations based on clinical data in order to provide 2 or 3 time-points, which can be used for accurate determination of the AUC [12,13]. For the estimation of unbound drug (the amount of drug that reaches the tissues) it is important to have information on drug–protein binding as only the unbound drug reaches the target site of infection [14]. More advanced TDM includes drug susceptibility in addition to using solely drug concentrations. The main PK/PD indexes used for optimization of TB therapy are AUC or $(f)AUC/MIC$ (minimal inhibitory concentration), $(f)C_{max}/MIC$ and

Article highlights

- TDM could have an important role in prevention of acquired drug resistance associated with low exposure.
- Pharmacokinetic/pharmacodynamic considerations could help clinicians select the right dose for optimization of therapy.
- Implementing optimal sampling strategies for TDM will be a game changer in implementation of precision dosing.
- Special consideration needs to be given to vulnerable subpopulations – e.g. children, HIV positive/diabetic patients and during renal and hepatic impairment.
- TDM will only be beneficial if sufficient access and short turn around time can be guaranteed at community, regional and central level.

This box summarizes key points contained in the article.

(*f*)/T (time)/MIC. These are then derived from previously described hollow fiber infection models, animal studies as well as from clinical studies. It has been well presented in a review by Dheda *et al* that low exposure to TB drugs, as a result of low drug penetration and, pharmacokinetic variability is one of the main risk factors for development of drug resistance, for example, for fluoroquinolones [15,16]. The TB treatment guidelines include suggestions whether to commence TDM for specific drugs (e.g. fluoroquinolones, linezolid and aminoglycosides and specific situations like HIV, diabetes, toxicity, failure of sputum culture conversion in case of proven drug susceptibility, and drug–drug interactions) [6,7,17].

TDM, however, is rarely performed in TB endemic settings due to its perceived costs/technical constraints [18]. Recent developments in the field of alternative and sampling strategies is changing the landscape of traditional TDM [18,19]. Some methods may be more user friendly for low resource settings, such as finger prick blood spots (dried blood spot method) or saliva. These could be suitable alternative matrixes to predict drug concentrations in serum/plasma [19–21]. Similarly, limited sampling strategies that utilizes two- to three-sampling time points for estimation of pharmacokinetic parameters, reduces sampling burden on both patients and clinicians [13,22]. Using multiple linear regression equations, concentrations measured at optimal sampling time points can accurately estimate AUC_{0-24} with an acceptable bias and imprecision of less than 15% (e.g. fluoroquinolones) [13,22].

The evidence linking low drug plasma concentrations and worse treatment outcomes is scarce in TB [4,5,23]. A recent systematic review and meta-analysis on first-line TB drugs concluded that low pyrazinamide and rifampicin concentrations might contribute to poor outcomes [5]. For ethambutol and isoniazid, the authors suggested that the relationship with poor treatment outcomes could not be defined, due to the wide therapeutic ranges applied to the TDM of these drugs [5]. Furthermore, the studies looking into TDM in TB are heterogeneous, including different study designs, drugs and regimens [4,5]. Still, there are clear benefits in utilizing an easy tool like TDM in TB patients. Currently, there are new drugs emerging, and PK studies in TB are continuing, which contributes further evidence for TDM in TB.

The aim of this review is to provide an update on newer drugs, novel dosing strategies and treatment regimens for TB. In addition, we provide an overview of TDM during concomitant therapy for hepatitis, HIV and during liver and kidney impairment. Finally, we present an overview of TDM in special patient populations – children and pregnant women.

2. Specific drugs

The drugs listed in this review are presented based on the WHO consolidated guidelines grouping of MDR-TB drugs and drugs for drug-susceptible TB (Table 1) [7]. The specific pharmacokinetic parameters and sampling strategies are presented in Table 2.

2.1. Drugs for drug-susceptible TB

2.1.1. Isoniazid

Isoniazid is a powerful first-line anti-TB drug with excellent early bactericidal activity [26]. Following administration, isoniazid is readily absorbed from gastrointestinal tract and penetrates all body fluid cavities, where concentrations are similar to serum. The C_{max} arrives approximately 0.75–2 h after administration and is expected to be 3–6 mg/L, the protein binding is described to be around 14% [2,27]. Based on hollow fiber model of TB, isoniazid efficacy is predicted by attainment of free $AUC_{0-24}/MIC > 567$ in the lung [28]. On the other hand, clinical study derived target AUC_{0-24} in blood is 52 mg*h/L [28,29]. This target can be utilized for TDM. A new susceptibility breakpoint for isoniazid was identified at MICs of 0.0312 and 0.0334 mg/L [15,28,30,31] (Table 2).

Pharmacokinetic studies also reveal that the currently used dose of isoniazid is sub-optimal and needs to be increased. In a shorter MDR-TB regimen, isoniazid dose of 900 mg/day is used. This is because not all resistance-conferring mutations lead to similar MIC increases. For instance, *katG* S315T confers 30-fold increase in MIC to isoniazid, in contrast, *inhA* c-15 t

Table 1. Drugs used in TB and MDR-TB.

Group	Medicine
Drug-susceptible TB	Isoniazid Rifampicin Rifabutin* Rifapentine* Ethambutol Pyrazinamide
Group A	Levofloxacin Moxifloxacin Bedaquiline Linezolid
Group B	Clofazimine Cycloserine/Terizidone
Group C	Delamanid and Pretomanid* Amikacin Streptomycin Ethionamide Prothionamide <i>p</i> -aminosalicylic acid Imipenem-cilastatin Meropenem

*added to the review, however not in the WHO classification

Table 2. Pharmacokinetic parameters of anti-TB drugs.

Drug	Normal adult dose	C _{max} (mg/L)	T _{max} (h)	AUC _{0-24h} (mg*h/L)	PK/PD index (serum/plasma)	T _{1/2} (h)	Protein binding	Sampling strategy	Pregnancy Category
Isoniazid	5 mg/kg daily	3–6	0.75–2	52	AUC _{0-24h} /MIC > 567 (lung) [26]	fast acetylators 1.5 h; slow acetylators 4h	14% (range 0–34%) [25]	2, 4, 8 h [31] 1, 2.5, 6 h [32]	A
Rifampicin [25]	10–20 mg/kg daily	8–24	3–6		AUC/MIC ≥ 271 C _{max} /MIC ≥ 175 [35–37]	3–5	88% [25]	1, 3, 8 h ^a [43]	C
Rifabutin [245–47]	300 mg daily	0.45–0.9	3–4	4.5 [48]		35–36	71%		B
Rifapentine [245–47]	600 mg daily	8–30	5	324 [49]		14–15	98%		C
Ethambutol	25 mg/kg daily	2–6	2–3		C _{max} /MIC > 0.46 [27]	Biphasic: 2–4, then 12–14	12% (range 4–24%) [25]	0, 2.5, 6 h [32]	A
Pyrazinamide	25–35 mg/kg daily	20–60 (recommend >35)	1–2	363 [27]	AUC _{0-24h} /MIC > 11.3 [27]	9	1% (range 0–7%) [25]	2, 4, 8 h [31] 0, 2, 6 h [32]	B
Levofloxacin [22,64]	750–1000 mg daily	8–13	1–2	150, if MIC is 1 mg/L or unknown	AUC/MIC > 146 ¹ AUC/MIC > 360 ² [70]	6–8	24–38% [25]	0, 4h ^a 0, 5 h ^a	C
Moxifloxacin [13]	400 mg daily	3–5	1–2	55, if MIC is 0.5 mg/L or unknown	fAUC/MIC > 130 [72]	7	30–50%	0, 4h ^a 0, 6 h ^a	
Bedaquiline [78,79]	400 mg daily for 2 weeks then 200 mg three times per week	2.8–3.3 (week 2) 1.7 (week 8) 1.3 (week 24)	4–6			5.5 months	>99%	0, 1.5, 6 h [32]	B
Linezolid [90,91]	600 mg daily	12–26	1–2	100 [96]		25 days	31%		C
Clofazimine [2,105,106]	100 mg daily	0.5–2.0	2.3		T > MIC = 30% [114–116]	15.79–25.1			
Cycloserine [110,111]	250–750 mg daily, sometimes divided as two doses	20–35	2			20.93–33.1 14.7 (IQR 9.5–14.8)		4h ^a 2, 7 h ^a 3, 8 h ^a	C
Terizidone [111]	250–750 mg daily	38.1	4	0–10 hours 319 mg/L*h					
Terizidone dosing, Cycloserine exposure [116,193]	250–500 mg	(IQR 32.6–47.2)							
Delamanid [194]	100 mg twice daily	1.35 initial 4.14 steady state	4			30–38	>99%		
Pretomanid [122]	200 mg once daily	1.4–2.6 initial 2.3–4.3 steady state	5			16	87%		
Streptomycin	15 mg/kg daily	35–45	0.5–1.5			5–6	35%	1, 4h	D
Amikacin [127]	25 mg TW 15 mg/kg daily	65–80 35–45	0.5–1.5		C _{max} /MIC > 75 AUC _{0-24h} /MIC > 103 [126]	3	0–11%	1, 4h	D
Prothionamide [137]	25 mg TW	65–80	3.0				30%		C
Ethionamide [3,139]	250–500 mg once or twice daily	1–5			fAUC/MIC > 10 [63,141]		50–60%		C
PAS [3,110]	250–500 mg once or twice daily 4000 mg two-three times daily	1–5 20–60							C

* = Multiple linear regression equations, # = Bayesian methods, & = using population pharmacokinetic model, TIW – three times per week
Further citations used for Table 1 [2,6,7,26]:

1. For maximum *M. tuberculosis* kill 2. For the prevention of acquired drug resistance

leads to only modest MIC increase at 0.2–1 mg/L [30]. For this reason, treating patients with low-level resistance to isoniazid with higher doses (15–20 mg/kg) have been associated with favorable clinical outcomes [15,30]. Furthermore, isoniazid metabolism occurs by acetylation. Based on acetylation status patients can be categorized into two or three groups: fast acetylators and slow acetylators, and when the data support it, heterogeneous fast [15,29,30]. Fast acetylators are at a risk of not attaining therapeutic concentrations of isoniazid due to short half-life (~1.5 h), whereas, prolonged half-life in slow acetylators (~4 h) may make them prone to drug-related toxicities, most notably peripheral neuropathy [15]. On the other hand, acetylation status is seldomly known. Based on multiple drug concentrations it is possible to classify a patient, who might be fast or slow acetylators. Most likely the acetylation status is unknown, thus multiple measurements after administration to calculate clearance might be the appropriate approach. Hepatotoxicity by far is the major side-effect of isoniazid. The concentration-relatedness of hepatotoxicity, however, is far from a settled matter. Pharmacogenomic-based dose individualization in NAT 2 slow- and fast- acetylators could be a promising strategy, especially in order to avoid under-dosing of fast-actylators [2,32]. Optimal sampling strategies of 2, 4, 8 h [33] and 1, 2.5, 6 h [34] have been proposed.

2.1.2. Rifampicin (rifampin)

Rifampicin is used in the treatment of drug-susceptible TB [35]. Rifampicin $C_{\max}$ is reached in approximately 1–3 hours and $t_{1/2}$ is estimated 3.5 hours with single doses, declining to 1–2 hours at steady state [36]. For many years the $C_{\max}$ in the range 8–24 mg/L, was considered the PK parameter to be used in TDM [36,37]. After reaching steady state in TB patients, it is not uncommon to find $C_{\max}$ values around 6 mg/L [37]. To achieve PK/PD targets, higher dosing should be used, and a higher $C_{\max}$ range can be proposed. The main PK/PD indexes used to guide therapy with rifampicin are $AUC/MIC \geq 271$ and $C_{\max}/MIC \geq 175$ [23,37–39]. Routine TDM of rifampicin is suggested as low 24-hour AUCs have proven to estimate poor long-term outcomes and both low AUC and $C_{\max}$ can cause acquired drug resistance [23,40]. However, PK parameters of rifampicin has been shown to have wide inter- and intra-patient variability and it has been suggested that therapy with rifampicin should use higher doses [37,40,41]. Moreover, rifampicin is known to induce its own metabolism (auto-induction) through increasing its clearance; however, this has shown to be similar in doses 450 mg and 600 mg daily [42,43]. Recent studies have shown that higher rifampicin doses lead to substantially higher efficacy than the standard doses. A rifampicin dose-ranging trial in DS-TB patients by Boeree and colleagues reported that doses (up to 35 mg/kg) were safe, well tolerated and further improved the extended early bactericidal activity in TB patients [41].

Commonly, sampling times for rifampicin are 2 and 6 hours after dose, to capture the peak concentration and potential delayed absorption [3,44]. An optimal sampling strategy of 1, 3 and 8 hours after dose has been suggested using

a pharmacokinetic model to estimate an accurate AUC_{0-24} [45]. This sampling strategy will provide more accurate results as the $T_{\max}$ can vary resulting in varied $C_{\max}$. In order to capture rifampicin concentrations after auto-induction takes place, TDM should take place at least 7 days into therapy (Table 2).

2.1.3. Rifabutin and rifapentine

Rifabutin and rifapentine are used for drug-susceptible TB as alternative for rifampicin. Protein binding is described for rifabutin approximately 71% and for rifapentine 98% [46,47]. The $C_{\max}$ for rifabutin is around 0.46 mg/L, the usual range is considered to be 0.45–0.9 mg/L and the $T_{\max}$ is expected at 3–4 h [2,48]. For rifapentine the $C_{\max}$ range to target that has been recommended is 8–30 mg/L and $T_{\max}$ is expected at 5 h [2]. The long half-life of 25–36 h (also reported to be 45 h) of rifabutin and 14–15 h of rifapentine need to be considered when performing TDM [2,47–49]. Rifabutin AUC_{0-24h} of 4.5 mg*h/L has been proposed in order to prevent (acquired) resistance [50]. For 600 mg daily dosing rifapentine AUC_{0-24h} of 324 (SD 143) mg *h/L has been reported [51]. For TDM of rifabutin it is suggested to use 3 h and 7 h and for rifapentine 6 h sampling [2].

As with rifampicin drug interactions by rifabutin are caused by induction of the CYP3A4 enzyme, however has documented to be of lower extent than rifampicin [48]. Furthermore, rifabutin exposure can also be reduced by other drugs, most significantly by antiretroviral efavirenz (reduction of 37% of AUC) and increased doses have been used [52]. The opposite effect, induction, has been described when co-administered with azoles and clarithromycin.

2.1.4. Ethambutol

Ethambutol is considered as a companion drug, valued for its protection against the development of resistance when combined with other first-line agents (isoniazid, rifampicin and pyrazinamide). Currently, ethambutol is prescribed at 25 mg/kg once daily dosing (max 1200 mg), although clinicians often prescribe smaller doses, around 15 mg/kg to avoid toxicity [7]. The $T_{\max}$ for ethambutol is expected around 2–3 hours and the half-life is biphasic first 2–4 h and then 12–14 h, $C_{\max}$ is expected to be 2–6 mg/L and protein binding is 12% [27,53,54]. Ethambutol exhibits dose-dependent efficacy which is predicted by both $C_{\max}/MIC$ and AUC_{0-24}/MIC . In the hollow fiber model of TB, $C_{\max}/MIC$ of 0.51 and AUC_{0-24}/MIC of 119 is identified as a target ratio in the lung whereas, in clinical studies $C_{\max}/MIC$ ratio of 0.46 in blood was associated with the likelihood of treatment success [29,55]. The susceptibility breakpoint for ethambutol is 4 mg/L. Ethambutol use can be associated with deteriorating visual acuity or red-green color discrimination (two manifestations of ocular toxicity). This is most likely to occur in patients with renal dysfunction, who are unable to clear the drug efficiently. Patients should be closely monitored for potential optic neuritis [26]. In particular, TDM usually is performed in patients with compromised renal function to prevent dose-dependent toxicity [26,56]. Pharmacokinetic parameters with optimal sampling strategies are presented in Table 2.

2.1.5. Pyrazinamide

Pyrazinamide is a key component of anti-TB regimens [26]. It is a prodrug that undergoes *in vivo* conversion to pyrazinoic acid. Resistance is associated with mutations in mycobacterial *pnc A* gene that codes for the enzymes responsible for conversion of pyrazinamide to pyrazinoic acid [57,58]. Currently, pyrazinamide is prescribed at 25–35 mg/kg daily dose (max 1600 mg/day) [7]. The $C_{\max}$ of pyrazinamide is expected to be 20–60 mg/L, the $T_{\max}$ around 1–2 h, the $T_{1/2}$ 9 h and the AUC_{0-24h} 363 mg*h/L [2,26,54]. Following oral administration, pyrazinamide is rapidly and almost completely absorbed. Intake with food reduces $C_{\max}$ by 17% and $T_{\max}$ by 80% [59]. In patients, this mg/kg dose has resulted in sub-therapeutic concentrations associated with the risk of treatment failure ($C_{\max}$ below 35 mg/L) and delayed sputum culture conversion ($C_{\max}$ below 58 mg/L) [23, 24, 60]. Higher doses might contribute to a more efficacious regimen for the treatment of both DS-TB and MDR-TB [61,62]. However, caution should be exercised, as higher doses might heighten the occurrence of hepatotoxicity and uric acid-related adverse effects.

Pyrazinamide efficacy is predicted by a free target $AUC_{0-24}/MIC > 209$ in the lung (hollow fiber model of tuberculosis) whereas, clinically derived target $AUC_{0-24} > 363$ mg*h/L and $AUC_{0-24}/MIC > 11.3$ was reported in the blood (Table 2) [29]. Moreover, two optimal sampling strategies with three time-points are presented in Table 2. The clinical susceptibility breakpoint of pyrazinamide is 50 mg/L, although this target comes with a number of caveats due to the difficulty of performing phenotypic susceptibility testing with pyrazinamide [63].

2.2. Drugs for MDR-TB and XDR-TB

2.2.1. Fluoroquinolones (Levofloxacin and Moxifloxacin)

Levofloxacin and moxifloxacin are recommended fluoroquinolones in the WHO list of second-line drugs for programmatic management of drug-resistant tuberculosis, and are used interchangeably [7]. Following oral administration, bioavailability of levofloxacin and moxifloxacin is 99% and 90%, respectively. Levofloxacin ingestion with food causes a moderate delay in its time to achieve maximum serum concentrations. $T_{\max}$ increases by 1 h and $C_{\max}$ reduces by 14 to 25% whereas, moxifloxacin absorption is not affected by food intake.

Both drugs exhibit high inter-individual variability. Moxifloxacin PK variability was found to be nine-fold in plasma on 400 mg/day [64]. Similarly, a striking four-fold difference was observed between the highest and lowest levofloxacin AUC_{0-24} in Nepalese patients on 750–1000 mg/day [19,65]. These findings corroborate results from other available studies [34,65–70]. Acquired fluoroquinolone resistance during standard treatment has become a serious concern, and was associated with poor outcomes in a prospective observational cohort study [71].

In the absence of data on TB bacteria, $AUC_{0-24}/MIC > 100-125$ was generalized for understanding dose-concentration-response relationship in TB patients [66,71]. Recently, the hollow fiber model on tuberculosis has established a levofloxacin total drug AUC_{0-24}/MIC target of 146 for maximum bacterial kill (EC_{80})

and 360 for the prevention of acquired drug resistance [72]. Earlier, a study by Gumbo and colleagues identified moxifloxacin $fAUC_{0-24}/MIC > 53$ associated with complete suppression of drug resistance mutant sub-population ($AUC_{0-24}/MIC > 106$, 30–50% protein bound) [73]. In another hollow fiber model study, Heinrichs and colleagues reported higher $fAUC/MIC > 130$ for moxifloxacin under conditions of acidic pH [74]. However, target derived from both pre-clinical *in vitro* and *in vivo* models have limitations. For instance, $C_{\max}/AUC_{0-24}$ achieved in animal models can be different from those seen in humans due to differences in metabolism and clearance, as a result, efficacy might vary. On the other hand, hollow fiber model misses the host-immune component and in humans it might be necessary to have a different concentration to penetrate cavity wall.

An ongoing randomized, blinded, phase II dose-finding trial (OptiQ trial, NCT 01918397) is evaluating AUC_{0-24}/MIC that provides shortest time to sputum culture conversion in TB patients [75,76]. This will be a first clinically validated levofloxacin target in TB patients. Nonetheless, it is important to note that debates regarding the precise PK/PD target does not imply a lack of confidence in TDM. Available data from clinical studies show that at least 25% of the patients on standard daily doses do not achieve the desired AUC_{0-24} , $C_{\max}$ and AUC_{0-24}/MIC for both levofloxacin and moxifloxacin [34,65–69]. Therefore, TDM has a crucial role in addressing the effect of inter-individual pharmacokinetic variabilities in patients by ensuring adequate drug exposure. In clinics, in the absence of actual MICs, one could aim to attain $C_{\max}$ and/or AUC_{0-24} targets mentioned in Table 2. However, practically, TDM without utilizing the actual MICs could be problematic because depending on the actual MICs (0.25, 0.5 or 1 mg/L for levofloxacin); desired AUC or $C_{\max}$ could be twice as high especially for patients infected with strains exhibiting higher MICs in order to attain the same AUC/MIC target. This could, however, be addressed by utilizing susceptibility breakpoint MICs for both levofloxacin and moxifloxacin (assuming worst-case scenario); but the risk of higher dosing cannot be ignored. For this, molecular tests with second-line drugs must be performed to provide information on susceptibility. Based on the distribution of MICs for particular mutations, specific dose could be selected. Caution should be applied, as the use of FQs have been associated with side-effects involving muscles, joints, tendons, nerves and the central nervous system. Moxifloxacin is known to prolong the QTc interval, but a direct link to moxifloxacin-induced fatal dysrhythmias is lacking [77]. Furthermore, it is imperative to identify patients on levofloxacin with diminished renal function, who may accumulate the drug, and to identify the concomitant use of corticosteroids, which may predispose to tendon rupture. Using optimal sampling strategies in order to estimate AUC_{0-24h} might be appropriate (Table 2) [13,22].

2.2.2. Bedaquiline

Bedaquiline (BDQ) was FDA approved for MDR-TB in 2012. In 2019, BDQ gained FDA approval as part of BPAL regimen for treatment of highly drug-resistant TB.

The typical trough and peak serum or plasma concentration of BDQ is approximately 0.9 (SD 0.5) mg/L, 2.4 (SD 0.8) mg/L at week 2 (loading phase), 0.6 (SD 0.3) mg/L, 1.5 (SD 0.6) mg/L at week 24 (maintenance phase) respectively, [78]. Bedaquiline has an exceptionally long half-life (5–6 months) and thus dosage adjustments should be made carefully. The exposure–response relationship in bedaquiline has been described with PK/PD modeling, where it was shown that half maximal effective concentration of bedaquiline is 1.42 mg/L and it was shown that besides dynamic exposure metrics, PK parameters like C_{min} and AUC_{0-24h} had significant effect on the response [79]. Variability about these typical values should be expected. Peak concentrations occur approximately 4 to 6 hours after an oral dose. Administering BDQ with food is recommended and increases the drug bioavailability, in healthy volunteers 2–2.4 fold increase of the AUC has been reported when administered with food [80,81].

The typical bedaquiline trough concentration is 0.73 to 0.96 mg/L at week 2 (24-hour sample), approximately 0.62 mg/L at week 8 (48-hour sample), and approximately 0.36 mg/L at week 24 (48-hour sample) [80,81] (Table 2). Bedaquiline penetration in cerebrospinal fluid was undetectably low [82]. Based on the average plasma concentration of 0.60 mg/L in humans and MIC distribution a clinical breakpoint of 0.25 mg/L was selected [83]. Although TDM has not been evaluated for bedaquiline, several situations where TDM could be of help were suggested, as acquired resistance has already been documented [83,84]. Moreover, optimal sampling strategies for BDQ have not been identified.

BDQ is metabolized by CYP3A4 to its less active M2 metabolite [81]. The most serious BDQ toxicities including prolonged QT interval and elevated liver enzymes are thought to be related to accumulation of M2. Due to potent CYP induction by rifamycins, co-administration of these drugs is not currently recommended [85,86]. In contrast, clofazimine does not appear to have significant effect on BDQ exposure [87].

2.2.3. Linezolid

Linezolid, an oxazolidinone antimicrobial, is an important candidate for TDM due to its narrow therapeutic window and toxicity that poses an issue, especially during TB therapy [88–91]. Linezolid has oral bioavailability of 100%, and it is metabolized through oxidation into inactive derivatives [92]. The expected C_{max} is 12–26 mg/L and T_{max} 1–2 hours, protein binding has described to be 31% [92,93]. Drug interactions with linezolid can be due to its effects as a nonselective monoamine oxidase inhibitor. Linezolid also interacts with rifampicin and clarithromycin, the former decreases linezolid concentrations, and the latter increases linezolid concentrations [94–96]. A study of MDR-TB patients showed that co-administration of linezolid and clarithromycin results in an 44% increase of linezolid AUC_{0-12h} [95].

Most frequently, linezolid is given once daily for mycobacterial infections to avoid toxicity during the prolonged treatment which exceed the licensed use of 28 days. Mitochondrial toxicity appears to be correlated with the trough concentration [97]. AUC

emerges as a significant predictor of efficacy when linezolid is combined with other drugs [98]. In a hollow fiber model AUC_{0-24h} of 600 mg dose has shown to be around 100 (107.5 ± 30.16) mg * h/L using a Monte Carlo simulation [98]. The optimal time of sampling to calculate AUC has been suggested to be C_{trough} (before administration) and 2 hours after administration (C_{peak} is estimated to be at 1–2 hours) [93,99] (Table 2). The reported C_{peak} and C_{trough} and ranges for 600 mg orally twice daily are 21.2 (SD 5.78) mg/L and 6.15 (SD 2.94) mg/L, respectively, [93].

For TB, doses as high as 1200 mg once daily have been studied, and these produced considerable toxicity [100]. A dose of 600 to 900 mg once daily probably is equally efficacious but with lower toxicity [101]. Even lower dosing of 300 mg twice daily has been suggested to be able to be efficacious [102]. Twenty-four-hour trough values less than 2 mg/L appear to minimize toxicity. The benefits of lower dosage regimens still need to be confirmed in larger trials [103,104]. In the absence of well-designed studies daily dose of 600 mg seems appropriate to balance between efficacy and toxicity [105]. TDM for linezolid is however mainly for toxicity as mentioned in order to reduce the dose, which becomes especially important in the long therapy duration for TB.

2.2.4. Clofazimine

Clofazimine is being used more frequently for highly resistant TB, and it has been used as part of shorter treatment regimens (less than 1 year) [7,106]. The normal range for clofazimine serum or plasma concentrations is 0.5 to 2.0 mg/L approximately 2–3 hours after an oral dose, although the T_{max} can vary widely [2,107,108] (Table 2). Clofazimine PK have been also described using simulations from a population model [109]. It was described that the AUC_{0-24h} , maximum and average concentrations of clofazimine were higher after 2 months of therapy compared to 2 weeks of therapy, which suggests accumulation. Moreover, the time to steady state was described to be higher in men than women – 105 days for men and 230 days for women [109]. Although there is not sufficient data on clofazimine TDM, for practical reasons, 2 h and 6 h post dose samples are used to distinguish between malabsorption and delayed absorption.

Clofazimine concentrates in tissues such as the skin and displays complex pharmacokinetics and a prolonged terminal elimination half-life (weeks long) [108]. A precise relationship between clofazimine concentrations and effect has not been established. However, one study observed delayed concentration-dependent antimicrobial activity in vitro [106]. Cardiotoxicity has been described as a rare side-effect during clofazimine therapy; however, it should be monitored [110,111]. Until more studies are completed, clofazimine plasma or serum concentrations primarily are useful for confirming that absorption is taking place. No optimal strategies for guiding therapy have been reported.

2.2.5. Cycloserine and terizidone

Cycloserine and terizidone (contains two cycloserine molecules) therapy has been complicated by frequent adverse effects on the central nervous system, ranging from mild

confusion or lethargy, all the way up to seizures [6]. The half-lives of cycloserine are both around 20–30 h and for cycloserine a $T_{\max}$ of 2 h and $C_{\max}$ of 20–35 mg/L has been described [112,113]. Due to its relatively long half-life, it has been suggested to wait 3–4 days for natural accumulation to occur. Peak concentrations of cycloserine are expected to be within 20–35 mg/L and the sample should be drawn at 2 and 6 hours, as delayed absorption can occur [3,114,115]. For terizidone, specific targets have not been set; however, $C_{\max}$ concentrations have been reported in multiple studies (Table 2). $T > \text{MIC} = 30\%$ has been used as a PK/PD index for cycloserine, which has been used in population pharmacokinetic modeling and confirmed in a hollow fiber model [116–118]. In order to achieve this target twice daily dosing is necessary especially at the beginning of therapy [116].

Adverse events are especially seen with elevated serum concentrations (over 35 mcg/ml); however, toxicity has also been described with lower concentrations [3,6,119]. Moreover, it has been proposed in a hollow fiber infection model that current dosing regimens might not be effective for MDR-TB and dosages should be increased to 500 mg twice daily. Higher doses also may be a good option for tuberculous meningitis, as cycloserine penetrates the CSF [116]. However, cycloserine also may complicate the assessment of mental status in a patient with meningitis.

Although the use of TDM for cycloserine predates that for most TB drugs, the origins of the range are not well documented. Very few clinical trial data are available for cycloserine from the time of its development. A typical range of 20–35 mg/L has been used with reasonable safety for decades, but its ability to predict either efficacy or safety is hard to prove (Table 2). Rather, it has a strong element of tradition. A study conducted in Northern Taiwan showed that 22% patients had delayed absorption, and a majority of them had lower than expected cycloserine concentrations, suggesting the need for TDM [114].

2.2.6. Delamanid

Delamanid is a nitroimidazole approved by the European Medicines Authority (EMA) for the treatment of MDR TB. The drug may enhance culture conversion in this population, especially with >6 months or more of therapy. However, this benefit has not been observed in XDR TB patients [120]. It may be useful as salvage therapy in combination with BDQ, but this combination poses a risk for QT prolongation since both drugs have been associated with this adverse effect [121,122]. Delamanid mean $C_{\max}$ 100 mg twice daily dosing is around 0.4 mg/L and $C_{\min}$ around 0.3 mg/L [123] (Table 2). Specific PK/PD index for delamanid is lacking as well as clinical PK data, further studies are needed before TDM before can be decided or if TDM is indicated.

2.2.7. Pretomanid

Pretomanid (PMD) gained FDA approval in late 2019 in combination with BDQ and linezolid (BPAL) for the treatment of highly resistant tuberculosis [100,124]. The typical peak serum or plasma concentration of pretomanid is around 2.0 mg/L, occurring about 5 hours after a 200 mg dose. Peak after

a single dose ranges from 1.4–2.6 mg/L, and at steady state, about 2.3–4.3 mg/L. Trough concentrations are about 1.0–2.4 mg/L (Table 2). Administering pretomanid with food is recommended and increases the drug bioavailability, both $C_{\max}$ and AUC have shown to be close to doubled during fed conditions in healthy adults [125]. In a Phase I clinical study it has been described that efavirenz reduces the AUC of pretomanid by 35% and rifampin reduces the AUC by 66% and lopinavir/ritonavir by 17% [126]. Another study assessing pretomanid effect on midazolam concluded that pretomanid does not induce or inhibit CYP3A4 in order to have a clinically meaningful effect [127]. TDM during concomitant administration with these drugs may be beneficial. As there is limited data available on this new drug, TDM could also be useful during malabsorption.

The most common adverse events observed during pretomanid therapy included peripheral neuropathy, anemia, GI upset, and elevated liver enzymes. Hepatic adverse effects were more common in HIV-positive patients compared to HIV-negative patients. Peripheral neuropathy and anemia are commonly associated in combination with linezolid therapy. Additional clinical trials are in progress [124].

2.2.8. Aminoglycosides (amikacin and streptomycin)

Amikacin has been in use for more than 40 years; still there are limited data available on its pharmacokinetics in relation to TB disease [128]. Besides, right dose and dosing strategies (daily 15 mg/kg vs intermittent 25 mg/kg three times weekly) are often debated [128]. Blood samples collected at 1 h and 4 h post dose reliably predicted AUC_{0-24} (Table 2) [129].

Notorious for its serious adverse reactions that include ototoxicity (hearing loss), vestibular toxicity and nephrotoxicity, this drug is a good candidate for TDM. When nephrotoxicity occurs amikacin can accumulate causing higher concentrations, which can lead to even further kidney damage, thus TDM during fluctuating kidney function and during kidney failure is especially warranted [130,131]. However, in younger patients who are diagnosed early kidney function can be easily monitored and does not pose as high risk as hearing loss [132]. In older patients with preexisting kidney failure therapy with aminoglycosides poses a higher risk for toxicity. The $C_{\max}/\text{MIC}$ ratio of 10.1 (at the site of infection) seems to be the primary efficacy parameter closely followed by $\text{AUC}_{0-24}/\text{MIC}$ ratio [128,133,134]. Due to its poor penetration in lung tissue, a target $C_{\max}/\text{MIC}$ ratio of 75 and $\text{AUC}_{0-24}/\text{MIC} > 103$ is desired in serum [128]. Van Altena *et al.* utilized a low $C_{\max}/\text{MIC}$ target of 20 and concluded that hearing loss was associated with a cumulative mg/kg doses of amikacin [132]. In this study, amikacin was used at lower mg/kg dose. Clearly, toxicity does not seem to be linked with the size and frequency of dosages but rather to increased age, cumulative days of therapy, and cumulative AUC [135,136]. Therefore, TDM should be performed to control toxicity resulting from long-term amikacin treatment, while at the same time optimizing therapy [128].

Streptomycin is used as a substitute for amikacin only when amikacin is not available or there is confirmed resistance to it. Recommended dose of streptomycin is 12–18 mg/kg [7]. The recommendations also cap the dosing at 1000 mg, which may lead to the under-dosing of large patients, particularly if they are not overweight. Pharmacokinetic parameters along with sampling time-points are shown in Table 2. Kanamycin and capreomycin are no longer recommended for use by the WHO based on observational data [137].

2.2.9. Ethionamide and prothionamide

Ethionamide and prothionamide, isonicotinic acid derivatives, frequently cause gastrointestinal toxicity (nausea, sometimes vomiting). They are reserved for MDR-TB when limited options exist, due to their limited efficacy and poor patient tolerance. Further, more effective newer drugs are currently available [6,110,138].

Ethionamide and prothionamide have very similar pharmacokinetics, and the $C_{\max}$ occurs around 2 hours for ethionamide and 3–4 hours for prothionamide [139,140]. Delayed and variable absorption can occur with ethionamide, especially if it is administered with food or other medications. Dosing with food may improve tolerability [3,140,141]. For ethionamide, the PK parameters may be more variable in TB patients compared to healthy volunteers; these are presented in Table 2 [141]. The usual concentration range for ethionamide and prothionamide $C_{\max}$ is 1–5 mg/L [3,141,142]. In order to observe delayed absorption, and to assess elimination, sampling at 2 and 6 hours post dose is suggested [3,141]. A $fAUC/MIC$ target of 10 has been proposed for 1.0-log kill, which has shown to be attained with daily dose of 750 mg and higher [65,143]. TDM of ethionamide could be useful in order to strive toward PK/PD targets, although patient tolerability often limits doses [143].

2.3. 2.2.10 p-Aminosalicylic acid

As with ethionamide and prothionamide, p-Aminosalicylic acid (PAS) is considered as a reserve agent, due to its limited potency and its side effects [6,144]. $C_{\max}$ of PAS is expected at 1–2 hours for immediate release dosage forms, and up to 6 hours post dose for different extended release dosage forms [145]. For doses up to 5,000 mg the $C_{\max}$ can range up to 50–100 mg/L, especially with immediate release tablets. However, for 4,000 mg (administered 2–3 times daily) extended release granules, a $C_{\max}$ of 20–60 mg/L occurs about 6 hours post dose (Table 2) [4,84,86,87]. PAS TDM allows for an assessment of absorption; some patients require single doses of 6,000 mg [146].

Gastrointestinal side effects are common with the older formulations of PAS; however, the granules have shown to cause less gastrointestinal toxicity [147,148]. Other side effects include hypothyroidism, hepatotoxicity and hypersensitivity reactions [110]. It has been shown that PAS clearance is more than 50% higher in patients with HIV infection treated with efavirenz [149]. Furthermore, the probability of target attainment from this study showed that 4000 mg twice daily

dosing for PAS is sufficient for exceeding the MIC for the dosing interval [149].

2.3.1. Beta-lactam antibiotics/beta-lactamase inhibitors

Ceftazidime/avibactam has been utilized in the treatment of rapid growing mycobacterial infections (RGM) such as *M. abscessus*, rather than slow-growing mycobacteria (e.g. MAC) [150]. However, given the increase in MDR/XDR TB cases, poor clinical outcomes, and the slow development of novel agents, more attention has been given to potentially repurposing beta-lactams, for example amoxicillin/clavulanate, for highly resistant TB [151]. Most beta-lactams have $C_{\max}$ values of about 70–80 mg/L per gram of dose, and short elimination half-lives of about 1 hour. The PK/PD target used for beta-lactam antibiotics is $T > MIC$, thus in a hospital setting prolonged infusions are recommended [152]. Drugs in this class are often unstable in human plasma, therefore accurately measuring drug concentrations can present logistical challenges. Most rely on renal elimination, and should be used with caution in patients with decreased renal function. Major limitations of many beta-lactams is that they must be given intravenously, and in combinations with a beta-lactamase inhibitor as *M. tuberculosis* has a highly active beta-lactamase [153]. As clavulanic acid is not available as a product it must be given as a combination of amoxicillin-clavulanic acid, even though the latter contributes little to the regimen but does cause gastrointestinal adverse effects [154].

Avibactam is a potent beta-lactamase inhibitor and was recently approved in combination with ceftazidime (CAV) for the treatment of gram-negative infections. Due to its good lung penetration [155], CAV was investigated for activity against *M. tuberculosis* in a hollow fiber model [156]. Neither ceftazidime nor avibactam alone effectively killed *M. tuberculosis*, however the combination demonstrated a sterilizing effect [156]. Up to 12 g daily in adults and 100 mg/kg three times daily in children was proposed as optimal regimens. The CAV exposure that achieved the same kill rates as those of the most active of the first-line drugs was a $\%T_{MIC}$ of $\geq 47\%$. The calculated the CAV exposure associated with maximal kill, which was a $\%T_{MIC}$ of $\geq 63\%$. Therefore, CAV has to be dosed at exposures exceeding a $\%T_{MIC}$ of 63% (that is, 63 to 100%) for optimal efficacy [156].

Clinical studies examining ertapenem for the treatment of MDR and XDR TB are limited, but a small (18 pts) retrospective study in the Netherlands examined the safety and pharmacokinetics of ertapenem [157]. Subsequently, a hollow fiber infection study was performed showing that 2000 mg as a once daily dose could be considered a more suitable dose for further clinical testing [158]. A prospective PK study evaluating a single 2000 mg ertapenem dose given as a 30 minute infusion showed that the PK/PD target of $\%T_{MIC} > 40\%$ was achieved in most patients [159].

Additional carbapenems have been investigated as potential components of drug regimens for MDR and XDR TB, but clinical studies remain limited [160,161]. Imipenem and meropenem have been included in the guidelines based on historical data and use. A comparison study found that

meropenem/clavulanate resulted in a shorter time to culture conversion and higher treatment success relative to imipenem/clavulanate [162].

3. TB in special patient populations

3.1. TDM in patients with hepatitis

Patients co-infected with hepatitis B or C and tuberculosis are more likely to experience drug-induced hepatotoxicity and hepatic dysfunction relative to patients without viral hepatitis [163]. A recent study suggests that prophylactically treating hepatitis B infection may reduce the incidence of liver failure in patients co-infected with TB [164].

Fortunately, several direct-acting antivirals (e.g. ledipasvir/sofosbuvir) that are superior to the conventional ribavirin and pegylated interferon regimens have been developed for the treatment of hepatitis C in the past decade. However due to the potential for drug interactions between these novel therapies and rifamycin-based anti-tuberculosis regimens, simultaneous treatment of these infections has largely been contraindicated. Few studies have directly examined simultaneous treatment of TB and hepatitis C [165,166]. While TDM is not routine performed for hepatitis drugs, it could be a valuable tool in order to navigate drug-drug interactions for coinfecting and co treated patients in the future [166].

3.2. TDM in patients with hepatic dysfunction

Managing anti-tuberculosis therapy in patients with liver disease presents several challenges. Multiple first-line medications can cause liver injury and occurs more frequently in patients with underlying liver disease [167]. Although the measurement of liver enzymes in serum can indicate that damage has been done to the liver, it cannot measure residual hepatic clearance potential for drugs.

Unfortunately, there is little information on serum concentrations of anti-tuberculosis drugs and hepatotoxicity. Furthermore, a small study found an association between elevated rifampin exposure and drug-induced hepatotoxicity [168]. Because of conflicting results, it is difficult to determine the utility of TDM to monitor for hepatotoxicity but can be considered in the management of therapy for patients with liver disease. In patients with hepatic dysfunction, it is prudent to measure serum concentrations of the TB drugs to make sure that adequate, but not excessive, drug concentrations are being obtained.

3.3. TDM in HIV-infected TB patients

TDM plays an important role in HIV-infected TB patients. There are multiple reasons for introducing TDM in this patient cohort. Firstly, in addition to TB drugs, these patients are receiving multiple antiretroviral drugs. Therefore, the potential for drug-drug interactions is high. The most recent MDR-TB guidelines include recommendations for the use bedaquiline and/or delamanid. Interactions between these drugs and the

HIV medications should always be considered [6,84]. Bedaquiline drug exposure has shown to be altered by strong CYP3A4 inducers [169,170].

Secondly, patients who are co-infected with HIV have been shown to have lower exposures of the first-line TB drugs. Reasons for this include underlying disease, diarrhea, and drug interactions [6,60,171,172]. Rifampicin, a potent CYP 450 enzyme inducer, causes drug interactions with many anti-retroviral drugs, including atazanavir/ritonavir, emtricitabine/tenofovir/raltegravir, darunavir/cobicistat [173]. Hepatically cleared HIV drugs likely will be affected by co-administration with rifamycins. An overview of overlapping toxicities between non-rifamycin based regimens and antiretroviral drugs have been well described in a recent clinical guideline focusing on MDR-TB [6].

It often is recommended to avoid co-administration of selected antiretrovirals with rifamycin-based TB drug regimens, however, that is not always possible. Rifabutin can be used instead of rifampicin in some situations, thus reducing but not eliminating the effects of hepatic enzyme induction. Also, there is a risk for overlapping toxicities between TB and HIV drugs. When multiple classes of drugs are started within a short period of time, often it is hard to tell which drug is causing the adverse effect (nausea, vomiting, rash, peripheral neuropathy, etc.) [6]. Further, the immune reconstitution inflammatory syndrome (IRIS) can be problematic in this circumstance. When the clinical situation allows for it, starting TB therapy, and then introducing the HIV therapy 2–8 weeks later, can mitigate these problems. However, in patients with very low CD4 counts, delays in starting HIV therapy may not be possible.

Drug interaction and pharmacokinetic/pharmacodynamic studies are still ongoing, especially with newer TB drugs and antiretrovirals. Since limited data are available, TDM can be used to monitor drug exposure in individual patients. A systematic review describing the interaction between HIV infection and first-line TB drugs suggested that HIV is one of factor leading to low drug exposures [174]. In addition, HIV patients can have delayed absorption, and this can be identified using TDM.

3.4. TDM in patients with renal impairment

Essential drug therapy cannot be avoided in patients with renal impairment. When dosage reductions are necessary, TDM is a great tool to ensure effectiveness while avoiding overdosing patients [175]. During TB therapy, special consideration should be given to the aminoglycosides, ethambutol, cycloserine, and levofloxacin, as these drugs can be accumulated with poor renal function [6,176,177]. It should be noted that serum creatinine is lagging indicator for kidney function, reflecting what already has transpired [178]. Applying TDM for patients on dialysis is useful, as dialysis is known to play a role in elimination of drugs [179]. It should be noted that most data are for hemodialysis, and patients undergoing peritoneal dialysis can respond differently. For patients receiving dialysis, a sample drawn before and after dialysis (allowing some time

for rebound) can be used to estimate how much was drug eliminated during dialysis. Ethambutol has been shown to be removed by hemodialysis, but may not be removed by peritoneal dialysis. Given the risk for ocular toxicity, consideration may be given to substituting moxifloxacin for ethambutol in patients with renal dysfunction. TDM has been suggested for guiding therapy in patients receiving dialysis [180,181].

3.5. TDM in children

Children are known to be under-represented in studies, and for TB this is not different. Pediatric dosing guidelines often are derived from adult guidelines. Depending on the age of the child, the absorption, distribution, metabolism and elimination vary and must always be taken into account [182]. For neonates, there are significant early changes in kidney function, drug protein binding and drug metabolism [182].

In order to decrease the blood volume used for TDM with children, dried blood spots (DBS) might be a good alternative where available [183]. It has been suggested that children tolerate TB therapy better than adults, but it can be difficult to monitor for adverse events [6]. However, a prospective study was conducted to assess drug-induced liver injury in children with TB and liver function tests were performed every 2 weeks, which could be feasible in routine clinical care [184]. The authors concluded that children with hypoalbuminemia and hepatotoxic comedications can be at higher risk in developing liver toxicity [184]. Thus here, TDM can be a good tool to assess drug exposure both for efficacy and for potential toxicities. Another reason to perform TDM in children is the wide pharmacokinetic variability that has been observed in children with TB [185].

3.6. TDM in pregnancy

Optimal tuberculosis treatment regimens during pregnancy still need to be established. A multitude of physiologic changes occur during pregnancy that can affect the pharmacokinetics of the treatment regimen and thus make optimal dosing challenging. These changes include increased cardiac output, increased clearance (hepatic and renal), and increased gastrointestinal transit time. This can further be complicated if the patient is also living with HIV and on an antiviral regimen with the potential for drug interactions. TDM is a vital tool to effectively monitor anti-tuberculosis therapy in these patients [186].

Two different studies examined the population pharmacokinetics of the first-line TB medications and did not find clinically relevant changes in exposure [187,188]. Authors found that rifampin clearance was moderately (14%) decreased during pregnancy in the third trimester, but dose adjustment was not required [188].

Data on second-line medications are sparse. Moxifloxacin and linezolid exposure has been reported to decrease during pregnancy compared to postpartum serum concentrations [189]. More studies examining the pharmacokinetics of anti-tuberculosis drugs are needed. An international expert panel

proposed that studies of MDR-TB, LTBI regimens in women with HIV and pharmacokinetics by stage of pregnancy to be of high priority. They also encouraged earlier inclusion of pregnant women in phase 3 trials where phase 2 safety and pharmacokinetic data from non-pregnant women is available [190]. The known FDA pregnancy categories are presented in Table 2 alongside other PK parameters.

4. Expert opinion

TB treatment has a long history of using 'one size fits all.' Although convenient, this has contributed to treatment failures, treatment relapses, and the selection of drug-resistant isolates.

An abundance of data has been published since the publication Alsultan and Peloquin in 2014 [2], which was a comprehensive review on TDM in TB. The current review focuses on covering also special populations children and pregnant women, but also provides an update for the previous publications. During the past decade many dosing regimens and strategies have changed and new research has provided further insight into which PK/PD indexes to be used in order to guide therapy.

While challenging in resource-limited circumstances, TDM offers the clinician the opportunity to individualize and optimize drug exposure early in treatment. It is true that not every location will have an LC MS-MS [9]. But excellent work can be done with relatively inexpensive HPLC UV systems that are not as demanding on the purity of reagents and the training of the chemists [191]. Ideally cheap and fast point-of-care test should be available to truly implement TDM in every setting to benefit all patients. Semi-quantitative test could be a solution to preselect patients that actually would require TDM [192]. There is a good example based on DBS how to introduce TDM into practice. Ghimire *et al.* have proposed a strategy how to implement TDM in the form of DBS into the three tiers of World Health Organization (WHO) tuberculosis diagnostics. The sampling could be done on a peripheral and intermediate level, when the measuring can be done at the central level laboratories [18]. It is more probable than on a central level the results would be more credible as high volume of samples require robust and reproducible methodology. Moreover, this leads to the approach suggested by Alffenaar *et al* that specific key drugs (rifampicin, pyrazinamide, isoniazid, levofloxacin, moxifloxacin and linezolid) should be screened on community level (peripheral) and phenotypic drug susceptibility and drug exposure should be determined on a regional level [29]. The need for guidance on implementing TDM for TB is definitely warranted, especially guidance is needed from WHO [193].

PK/PD provides the necessary insight into drug action in order to extract the full benefit of the drugs. Current short course regimens are 6 or more months long. The longer treatment continues, the greater the opportunity to acquire drug resistance. Individualization of treatment takes into account the TB isolate (degree of drug susceptibility), the extent of disease (including cavities, abscesses, penetration into bone or the

central nervous system), liver and kidney function. Rather than 'one size fits all,' the regimen is tailored to the patient so that it fits the patient. Once the initial regimen is started, its suitability is confirmed using TDM, as well as the more typical clinical and microbiological assessments. This approach provides the patient with the best chance to avoid negative treatment outcomes. Clearly, the evaluation of such approach in a randomized trial would advance the implementation of TDM. Currently, the biggest hurdles for the implementation of TDM for TB are funding and training of local staff.

Funding

Anne-Grete Mårtson was supported by the Foundation 'De Drie Lichten' in The Netherlands and was funded by Marie Skłodowska-Curie Actions [grant agreement no. 713660—PRONKJEWAIL—H2020-MSCA-COFUND-2015].

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

ORCID

Anne-Grete Mårtson <http://orcid.org/0000-0001-6478-1959>

References

Papers of special note have been highlighted as either of interest (*) or of considerable interest (**) to readers.

- Zuur MA, Bolhuis MS, Anthony R, et al. Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis. *Expert Opin Drug Metab Toxicol*. 2016;12:509–521.
- Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. *Drugs*. 2014;74:839–854.
- A review of TDM in tuberculosis drugs, covering widely similar topics that are in the current paper**
- Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. *Drugs*. 2002;62:2169–2183.
- Mota L, Al-Efraij K, Campbell JR, et al. Therapeutic drug monitoring in anti-tuberculosis treatment: a systematic review and meta-analysis. *Int J Tuberc Lung Dis*. [Internet]. 2016;20:819–826. Available from: <https://pubmed.ncbi.nlm.nih.gov/27155187>
- Perumal R, Naidoo K, Naidoo A, et al. A systematic review and meta-analysis of first-line tuberculosis drug concentrations and treatment outcomes. *Int J Tuberc Lung Dis*. [Internet]. 2020;24:48–64. Available from: <https://pubmed.ncbi.nlm.nih.gov/32005307>
- Nahid P, Mase SR, Migliori GB, et al. Treatment of drug-resistant tuberculosis. an official ATS/CDC/ERS/IDSA clinical practice guideline. *Am J Respir Crit Care Med*. [Internet]. 2019;200:e93–e142. Available from: .
- ATS/CDC/ERS/IDSA treatment guideline for drug-resistant tuberculosis, the document includes also special patient groups**
- WHO. WHO consolidated guidelines on drug-resistant tuberculosis treatment. 2019 [Internet]. Geneva; 2019 [cited 2020 Sep 21]. Available from: <https://www.who.int/tb/publications/2019/consolidated-guidelines-drug-resistant-TB-treatment/en/>.
- WHO guideline focusing on drug-resistant tuberculosis.**
- Peloquin CA; [Internet]. Tuberculosis Drug Serum Levels. *Clin Infect Dis*. 2001;33:584–585. Available from:..
- [Internet]; Kuhl J, Sturkenboom MGG, Ghimire S, et al. Mass spectrometry for therapeutic drug monitoring of anti-tuberculosis drugs. *Clin Mass Spectrom*. 2019;14:34–45. Available from: <http://www.sciencedirect.com/science/article/pii/S2376999818300151>
- Buclin T, Thoma Y, Widmer N, et al. The steps to therapeutic drug monitoring: a structured approach illustrated with imatinib [Internet]. *Front Pharmacol*. 2020;177. Available from: <https://www.frontiersin.org/article/10.3389/fphar.2020.00177>
- Srivastava S, Gumbo T. In vitro and in vivo modeling of tuberculosis drugs and its impact on optimization of doses and regimens. *Curr Pharm Des*. 2011;17:2881–2888.
- Alffenaar J-WC, Kosterink JGW, van Altena R, et al. Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis. *Ther Drug Monit*. 2010;32:97–101.
- van den Elsen SHJ, Sturkenboom MGG, Akkerman OW, et al. Limited sampling strategies using linear regression and the Bayesian approach for therapeutic drug monitoring of Moxifloxacin in tuberculosis patients. *Antimicrob Agents Chemother*. 2019;63:e00384–19.
- Gonzalez D, Schmidt S, Derendorf H. Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents. [Internet]. *Clin Microbiol Rev*. 2013;26:274–288. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/23554417>
- Dheda K, Gumbo T, Maartens G, et al. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. *Lancet Respir Med*. 2017 Mar 15;291–360.
- Important overview of the epidemiology, pathogenesis and emergence of resistance in tuberculosis.**
- Alffenaar J-WC, Gumbo T, Aarnoutse RE. Acquired drug resistance: we can do more than we think! *Clin Infect Dis*. 2015;60:969–970. Available from:.. [Internet].
- van der Burgt EPM, Sturkenboom MGG, Bolhuis MS, et al. End TB with precision treatment! *Eur Respir J*. [Internet]. 2016;47:680 LP–682. Available from: <http://erj.ersjournals.com/content/47/2/680.abstract>
- Ghimire S, Bolhuis MS, Sturkenboom MGG, et al. Incorporating therapeutic drug monitoring into the World Health Organization hierarchy of tuberculosis diagnostics. *Eur Respir J England*. 2016;1867–1869.
- A concise overview how to implement TDM into practice using the WHO hierarchy of tuberculosis diagnostics**
- Ghimire S, Maharjan B, Jongedijk EM, et al. Evaluation of saliva as a potential alternative sampling matrix for therapeutic drug monitoring of levofloxacin in patients with multidrug-resistant tuberculosis. *Antimicrob Agents Chemother*. 2019;63:e02379–18.
- Vu DH, Koster RA, Alffenaar JWC, et al. Determination of moxifloxacin in dried blood spots using LC-MS/MS and the impact of the hematocrit and blood volume. *J Chromatogr B Anal Technol Biomed Life Sci*. 2011;879:1063–1070.
- Alffenaar J-WC, Jongedijk EM, van Winkel CAJ, et al. A mobile microvolume-UV/VIS spectrophotometer for the measurement of levofloxacin in saliva. *J Antimicrob Chemother*. 2020. DOI:10.1093/jac/dkaa420.
- van den Elsen SHJ, Sturkenboom MGG, Van't Bovenind-Vrubleuskaya N, et al. Population Pharmacokinetic Model and

- Limited Sampling Strategies for Personalized Dosing of Levofloxacin in Tuberculosis Patients. *Antimicrob Agents Chemother.* 2018;62:e01092–18.
23. Pasipanodya JG, McIlleron H, Burger A, et al. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. *J Infect Dis.* 2013;208:1464–1473.
 - **Publication confirming that low AUCs are predictive of clinical outcomes in tuberculosis patients**
 24. Court R, Wiesner L, Stewart A, et al. Steady state pharmacokinetics of cycloserine in patients on terizidone for multidrug-resistant tuberculosis. *Int J Tuberc Lung Dis.* 2018;22:30–33.
 25. Sasahara K, Shimokawa Y, Hirao Y, et al. Pharmacokinetics and metabolism of delamanid, a novel anti-tuberculosis drug, in animals and humans: importance of albumin metabolism in vivo. *Drug Metab Dispos.* [Internet]. 2015;43:1267 LP– 1276. Available from: <http://dmd.aspetjournals.org/content/43/8/1267.abstract>
 26. Peloquin C. The role of therapeutic drug monitoring in mycobacterial infections. *Microbiol Spectr.* 2017;5:TNM17-0029-2016. DOI:10.1128/microbiolspec.
 27. Alghamdi WA, Al-Shaer MH, Peloquin CA. Protein binding of first-line antituberculosis drugs. [Internet]. *Antimicrob Agents Chemother.* 2018;62:e00641–18. Available from: <http://aac.asm.org/content/62/7/e00641-18.abstract>
 28. Gumbo T. New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. *Antimicrob Agents Chemother.* 2010;54:1484–1491.
 29. Alffenaar J-WC, Gumbo T, Dooley KE, et al. Integrating pharmacokinetics and pharmacodynamics in operational research to end tuberculosis. *Clin Infect Dis an off Publ Infect Dis Soc Am.* 2020;70:1774–1780.
 - **The latest comprehensive summary on optimization therapy of anti-tuberculous agents through using PK and PD**
 30. Lange C, Alghamdi WA, Al-Shaer MH, et al. Perspectives for personalized therapy for patients with multidrug-resistant tuberculosis. *J Intern Med.* 2018;284:163–188.
 31. Zuur MA, Pasipanodya JG, van Soolingen D, et al. Intermediate susceptibility dose-dependent breakpoints for high-dose rifampin, isoniazid, and pyrazinamide treatment in multidrug-resistant tuberculosis programs. *Clin Infect Dis an off Publ Infect Dis Soc Am.* 2018;67:1743–1749.
 32. Azuma J, Ohno M, Kubota R, et al. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. *Eur J Clin Pharmacol.* 2013;69:1091–1101.
 33. Saktiawati AMI, Harkema M, Setyawan A, et al. Optimal sampling strategies for therapeutic drug monitoring of first-line tuberculosis drugs in patients with tuberculosis. *Clin Pharmacokinet.* 2019;58:1445–1454.
 34. Magis-Escurra C, HMJ L-N, Alffenaar JWC, et al. Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin. *Int J Antimicrob Agents.* 2014;44:229–234.
 35. WHO. Guidelines for treatment of drug-susceptible tuberculosis and patient care (2017 update) [Internet]. 2017 [cited 2020 Sep 21]. Available from: https://www.who.int/tb/publications/2017/dstb_guidance_2017/en/
 36. Verbeeck RK, Gunther G, Kibuule D, et al. Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring. *Eur J Clin Pharmacol.* 2016;72:905–916.
 37. [Internet]; Stott KE, Pertinez H, Sturkenboom MGG, et al. Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis. *J Antimicrob Chemother.* 2018;73:2305–2313. Available from: <https://pubmed.ncbi.nlm.nih.gov/29701775>
 38. Jayaram R, Gaonkar S, Kaur P, et al. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. *Antimicrob Agents Chemother.* 2003;47:2118–2124.
 39. [Internet]; Gumbo T, Louie A, Deziel MR, et al. Concentration-Dependent Mycobacterium tuberculosis Killing and Prevention of Resistance by Rifampin. *Antimicrob Agents Chemother.* 2007;51:3781 LP– 3788. Available from: <http://aac.asm.org/content/51/11/3781.abstract>
 40. Ray J, Gardiner I, Marriott D. Managing antituberculosis drug therapy by therapeutic drug monitoring of rifampicin and isoniazid. *Intern Med J.* 2003;33:229–234.
 41. Boeree MJ, Heinrich N, Aarnoutse R, et al. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. *Lancet Infect Dis.* 2017;17:39–49.
 42. Smythe W, Khandelwal A, Merle C, et al. A semimechanistic pharmacokinetic-enzyme turnover model for rifampin autoinduction in adult tuberculosis patients. *Antimicrob Agents Chemother.* 2012;56:2091–2098.
 43. Loos U, Musch E, Jensen JC, et al. Pharmacokinetics of oral and intravenous rifampicin during chronic administration. *Klin Wochenschr.* 1985;63:1205–1211.
 44. Magis-Escurra C, van den Boogaard J, Ijdema D, et al. Therapeutic drug monitoring in the treatment of tuberculosis patients. *Pulm Pharmacol Ther.* [Internet]. 2012;25:83–86. Available from: <http://www.sciencedirect.com/science/article/pii/S1094553911001660>
 45. Sturkenboom MGG, Mulder LW, de Jager A, et al. Pharmacokinetic modeling and optimal sampling strategies for therapeutic drug monitoring of rifampin in patients with tuberculosis. *Antimicrob Agents Chemother.* [Internet]. 2015;59:4907 LP– 4913. Available from: <http://aac.asm.org/content/59/8/4907.abstract>
 46. Skinner MH, Hsieh M, Torseth J, et al. Pharmacokinetics of rifabutin. *Antimicrob Agents Chemother.* [Internet]. 1989;33:1237 LP– 1241. Available from: <http://aac.asm.org/content/33/8/1237.abstract>
 47. Munsiff SS, Kambili C, Ahuja SD. Rifapentine for the Treatment of Pulmonary tuberculosis. *Clin Infect Dis.* 2006;43:1468–1475. Available from: [Internet].
 48. Skinner MH, Blaschke TF. Clinical Pharmacokinetics of Rifabutin. *Clin Pharmacokinet.* 1995;28:115–125. Available from: [Internet].
 49. Weiner M, Bock N, Peloquin CA, et al. Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy. *Am J Respir Crit Care Med.* 2004;169:1191–1197.
 50. Weiner M, Benator D, Burman W, et al. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. *Clin Infect Dis an off Publ Infect Dis Soc Am.* 2005;40:1481–1491.
 51. Savic RM, Weiner M, MacKenzie WR, et al. Defining the optimal dose of rifapentine for pulmonary tuberculosis: exposure-response relations from two phase II clinical trials. *Clin Pharmacol Ther.* [Internet]. 2017 /March/02;102:321–331. Available from: <https://pubmed.ncbi.nlm.nih.gov/28124478>
 52. Weiner M, Benator D, Peloquin CA, et al. Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis. *Clin Infect Dis an off Publ Infect Dis Soc Am.* 2005;41:1343–1349.
 53. Zhu M, Burman WJ, Starke JR, et al. Pharmacokinetics of ethambutol in children and adults with tuberculosis. *Int J Tuberc Lung Dis off J. Int Union against Tuberc Lung Dis.* 2004;8:1360–1367.
 54. Denti P, Jeremiah K, Chigutsa E, et al. Pharmacokinetics of isoniazid, pyrazinamide, and ethambutol in newly diagnosed pulmonary TB 'patients in Tanzania. *PLoS One.* [Internet]. 2015;10:e0141002–e0141002. Available from: <https://pubmed.ncbi.nlm.nih.gov/26501782>
 55. Srivastava S, Musuka S, Sherman C, et al. Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in

- Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol. *J Infect Dis*. 2010;201:1225–1231.
56. Hasenbosch RE, Alffenaar JWC, Koopmans SA, et al. Ethambutol-induced optical neuropathy: risk of overdosing in obese subjects. *Int J Tuberc Lung Dis* off J Int Union against Tuberc Lung Dis. 2008;12:967–971.
 57. Zhang Y, Mitchison D. The curious characteristics of pyrazinamide: a review. *Int J Tuberc Lung Dis* off J. Int Union against Tuberc Lung Dis. 2003;7:6–21.
 58. Millard JD, Mackay EA, Bonnett LJ, et al. The impact of inclusion, dose and duration of pyrazinamide (PZA) on efficacy and safety outcomes in tuberculosis: systematic review and meta-analysis protocol. *Syst Rev*. 2019;8:329.
 59. Peloquin CA, Bulpitt AE, Jaresko GS, et al. Pharmacokinetics of pyrazinamide under fasting conditions, with food, and with antacids. *Pharmacotherapy*. 1998;18:1205–1211.
 60. Chideya S, Winston CA, Peloquin CA, et al. Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. *Clin Infect Dis an off Publ Infect Dis Soc Am*. 2009;48:1685–1694.
 61. East African-British Medical Research Councils. Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Third report. 1974;2:237–240.
 62. Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. *Lancet*. 1972;1:1079–1085.
 63. Gumbo T, Dona CSWS, Meek C, et al. Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs. *Antimicrob Agents Chemother*. 2009;53:3197–3204.
 64. Pranger AD, van Altena R, Aarnoutse RE, et al. Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience. *Eur Respir J*. 2011;38:888–894.
 65. Deshpande D, Pasipanodya JG, Mpagama SG, et al. Ethionamide pharmacokinetics/pharmacodynamics-derived dose, the role of MICs in clinical outcome, and the resistance arrow of time in multidrug-resistant tuberculosis. *Clin Infect Dis*. [Internet]. 2018;67:S317–S326. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/30496457>
 66. Peloquin CA, Hadad DJ, Molino LPD, et al. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. *Antimicrob Agents Chemother*. 2008;52:852–857.
 67. Thwaites GE, Bhavnani SM, Chau TTH, et al. Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis. *Antimicrob Agents Chemother*. 2011;55:3244–3253.
 68. Alffenaar JWC, van Altena R, Bökkerink HJ, et al. Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis. *Clin Infect Dis an off Publ Infect Dis Soc Am*. 2009;49:1080–1082.
 69. Manika K, Chatzika K, Zarogoulidis K, et al. Moxifloxacin in multidrug-resistant tuberculosis: is there any indication for therapeutic drug monitoring? *Eur Respir J*. 2012;40:1051–1053.
 70. Van't Bovenind-Vrubleuskaya N, Seuruk T, van Hateren K, et al. Pharmacokinetics of Levofloxacin in multidrug- and extensively drug-resistant tuberculosis patients. *Antimicrob Agents Chemother*. 2017;61:e00343–17.
 71. Cegielski JP, Dalton T, Yagui M, et al. Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis. *Clin Infect Dis an off Publ Infect Dis Soc Am*. 2014;59:1049–1063.
 - **This paper focuses on acquired drug resistance and the importance of drug exposure in resistance**
 72. Deshpande D, Pasipanodya JG, Mpagama SG, et al. Levofloxacin pharmacokinetics/pharmacodynamics, dosing, susceptibility breakpoints, and artificial intelligence in the treatment of multidrug-resistant tuberculosis. *Clin Infect Dis an off Publ Infect Dis Soc Am*. 2018;67:S293–S302.
 73. Gumbo T, Louie A, Deziel MR, et al. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. *J Infect Dis*. 2004;190:1642–1651.
 - **Important publication using hollow fiber infection model to present dose selection in order to find a dose to suppress resistance**
 74. Heinrichs MT, Drusano GL, Brown DL, et al. Dose optimization of moxifloxacin and linezolid against tuberculosis using mathematical modeling and simulation. *Int J Antimicrob Agents*. 2019;53:275–283.
 75. Bouton TC, Phillips PPJ, Mitnick CD, et al. An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial. *Trials*. 2017;18:563.
 76. Peloquin CA, Phillips PPJ, Mitnick CD, et al. Increased doses lead to higher drug exposures of Levofloxacin for treatment of tuberculosis. *Antimicrob Agents Chemother*. 2018 Sep 24;62(10):e00770–18.
 77. Nunn AJ, Phillips PPJ, Meredith SK, et al. A trial of a shorter regimen for Rifampin-resistant tuberculosis. *N Engl J Med*. 2019;380:1201–1213.
 78. Svensson EM, Dosne A-G, Karlsson MO. Population pharmacokinetics of Bedaquiline and metabolite M2 in patients with drug-resistant tuberculosis: the effect of time-varying weight and Albumin. *CPT Pharmacometrics Syst Pharmacol*. 2016;5:682–691.
 79. Svensson EM, Karlsson MO. Modelling of mycobacterial load reveals bedaquiline's exposure-response relationship in patients with drug-resistant TB. *J Antimicrob Chemother*. 2017;72:3398–3405.
 80. Diacon AH, Pym A, Grobusch M, et al. The Diarylquinoline TMC207 for multidrug-resistant tuberculosis. *N Engl J Med*. 2009;360:2397–2405. Available from: [Internet].
 81. van Heeswijk RPG, Dannemann B, Hoetelmans RMW. Bedaquiline: a review of human pharmacokinetics and drug-drug interactions. *J Antimicrob Chemother*. 2014;69:2310–2318. Available from: [Internet].
 82. Akkerman OW, Odish OFF, Bolhuis MS. et al. Pharmacokinetics of Bedaquiline in cerebrospinal fluid and serum in multidrug-resistant tuberculous meningitis. *Clin Infect Dis an off Publ Infect Dis Soc Am United States*. 2016; 523–524.
 83. Nguyen TVA, Anthony RM, A-L B, et al. Bedaquiline resistance: its emergence, mechanism, and prevention. *Clin Infect Dis an off Publ Infect Dis Soc Am*. 2018;66:1625–1630.
 84. Alffenaar JWC, Akkerman OW, Tiberi S, et al. Should we worry about bedaquiline exposure in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis? *Eur Respir J England*. 2020.
 85. Healan AM, Salata RA, Griffiss JM, et al. Effects of Rifamycin coadministration on Bedaquiline desmethylation in healthy adult volunteers. *Clin Pharmacol Drug Dev*. 2019;8:436–442.
 86. Healan AM, Griffiss JM, Proskin HM, et al. Impact of Rifabutin or Rifampin on Bedaquiline safety, tolerability, and pharmacokinetics assessed in a randomized clinical trial with healthy adult volunteers. *Antimicrob Agents Chemother*. 2017 Dec 21;62(1):e00855–1717.
 87. Maartens G, Brill MJE, Pandie M, et al. Pharmacokinetic interaction between bedaquiline and clofazimine in patients with drug-resistant tuberculosis. *Int J Tuberc Lung Dis off J. Int Union against Tuberc Lung Dis*. 2018;22:26–29.
 88. Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. *N Engl J Med*. [Internet]. 2012;367:1508–1518. Available from: <https://pubmed.ncbi.nlm.nih.gov/23075177>

89. Lee M, Cho SN, Barry CE 3rd, et al. Linezolid for XDR-TB—final study outcomes. *N Engl J Med*. [Internet]. 2015;373:290–291. Available from: <https://pubmed.ncbi.nlm.nih.gov/26176401>
90. Tang S, Yao L, Hao X, et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China. *Eur Respir J*. [Internet]. 2014 /September/18;45:161–170. Available from: <https://pubmed.ncbi.nlm.nih.gov/25234807>
91. Wasserman S, Meintjes G, Maartens G. Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index. *Expert Rev Anti Infect Ther*. [Internet]. 2016 /August/ 27;14:901–915. Available from: <https://pubmed.ncbi.nlm.nih.gov/27532292>
92. Zyvox 600 mg film-coated tablets summary of product characteristics [Internet]. 2018 [cited 2020 Sep 21]. Available from: <https://www.medicines.org.uk/emc/medicine/9857#gref>.
93. Moellering RC Jr. Linezolid: the First Oxazolidinone Antimicrobial. *Ann Intern Med*. 2003;138:135–142. Available from: [Internet].
94. Bolhuis MS, Akkerman OW, Sturkenboom MGG, et al. Different underlying mechanism might explain the absence of a significant difference in area under the concentration-time curve of linezolid for different ABCB1 genotypes. *Ther Drug Monit United States*. 2019; p. 253–254.
95. Bolhuis MS, van Altena R, van Soolingen D, et al. Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients. *Eur Respir J*. 2013;42:1614–1621.
96. Ashizawa N, Tsuji Y, Kawago K, et al. Successful treatment of methicillin-resistant *Staphylococcus aureus* osteomyelitis with combination therapy using linezolid and rifampicin under therapeutic drug monitoring. *J Infect Chemother*. [Internet]. 2016;22:331–334. Available from: <http://www.sciencedirect.com/science/article/pii/S1341321X15002846>
97. Song T, Lee M, Jeon H-S, et al. Linezolid trough concentrations correlate with mitochondrial toxicity-related adverse events in the treatment of chronic extensively drug-resistant tuberculosis. *EBioMedicine* [Internet]. 2015;2:1627–1633. Available from: <https://pubmed.ncbi.nlm.nih.gov/26870788>.
98. Srivastava S, Magombedze G, Koeuth T, et al. Linezolid dose that maximizes sterilizing effect while minimizing toxicity and resistance emergence for tuberculosis. *Antimicrob Agents Chemother*. 2017;61:e00751–17.
99. Kamp J, Bolhuis MS, Tiberi S, et al. Simple strategy to assess linezolid exposure in patients with multi-drug-resistant and extensively-drug-resistant tuberculosis. *Int J Antimicrob Agents*. [Internet]. 2017 /April/04;49:688–694. Available from: <https://pubmed.ncbi.nlm.nih.gov/28389352>
100. Conradie F, Diacon AH, Ngubane N, et al. Treatment of highly drug-resistant pulmonary tuberculosis. *N Engl J Med*. 2020;382:893–902.
101. Brown AN, Drusano GL, Adams JR, et al. Preclinical evaluations to identify optimal linezolid regimens for tuberculosis therapy. *MBio*. [Internet]. 2015;6:e01741. Available from: <https://pubmed.ncbi.nlm.nih.gov/26530386>
102. Millard J, Pertinez H, Bonnett L, et al. Linezolid pharmacokinetics in MDR-TB: a systematic review, meta-analysis and Monte Carlo simulation. *J Antimicrob Chemother*. 2018;73:1755–1762.
103. Bolhuis MS, Tiberi S, Sotgiu G, et al. Is there still room for therapeutic drug monitoring of linezolid in patients with tuberculosis? *Eur Respir J*. [Internet]. 2016;47:1288–1290. Available from: <https://pubmed.ncbi.nlm.nih.gov/27037319>
104. Bolhuis MS, van der Werf TS, Kerstjens HAM, et al. Treatment of multidrug-resistant tuberculosis using therapeutic drug monitoring: first experiences with sub-300 mg linezolid dosages using in-house made capsules. *Eur. Respir. J. England*. 2019 Dec 4;54 (6):1900580.
105. Bolhuis MS, Akkerman OW, Sturkenboom MGG, et al. Linezolid-based regimens for multidrug-resistant tuberculosis (TB): a systematic review to establish or revise the current recommended dose for TB treatment. *Clin Infect Dis an off Publ Infect Dis Soc Am*. 2018;67:S327–S335.
106. Ammerman NC, R V S, Tapley A, et al. Clofazimine has delayed antimicrobial activity against *Mycobacterium tuberculosis* both in vitro and in vivo. *J Antimicrob Chemother*. 2017;72:455–461.
107. Garrelts JC. Clofazimine: a review of its use in leprosy and *Mycobacterium avium* complex infection. [Internet]. DICP. 1991;25:525–531. Available from: <http://europepmc.org/abstract/MED/2068838>
108. Holdiness MR. Clinical pharmacokinetics of clofazimine. A review. *Clin Pharmacokinet*. 1989;16:74–85.
109. Abdelwahab MT, Wasserman S, Brust JCM, et al. Clofazimine pharmacokinetics in patients with TB: dosing implications. *J Antimicrob Chemother*. 2020 Nov;75(11):3269–3277. [Internet] Available from: DOI:10.1093/jac/dkaa310
110. Ramachandran G, Swaminathan S. Safety and tolerability profile of second-line anti-tuberculosis medications. *Drug Saf*. [Internet]. 2015;38:253–269. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/25676682>
111. Choudhri SH, Harris L, Butany JW, et al. Clofazimine induced cardiotoxicity—a case report. *Lepr Rev*. 1995;66:63–68.
112. Chang MJ, Jin B, Chae J-W, et al. Population pharmacokinetics of moxifloxacin, cycloserine, p-aminosalicylic acid and kanamycin for the treatment of multi-drug-resistant tuberculosis. *Int J Antimicrob Agents*. [Internet]. 2017 /April/10;49:677–687. Available from: <https://pubmed.ncbi.nlm.nih.gov/28408267>
113. Zítková L, Tousek J. Pharmacokinetics of cycloserine and terizidone. A comparative study. *Chemotherapy*. [Internet]. 1974;20:18–28. Available from: <https://pubmed.ncbi.nlm.nih.gov/4845674>
114. Hung W-Y, Yu M-C, Chiang Y-C, et al. Serum concentrations of cycloserine and outcome of multidrug-resistant tuberculosis in Northern Taiwan. *Int J Tuberc Lung Dis*. [Internet]. 2014;18:601–606. Available from: <https://pubmed.ncbi.nlm.nih.gov/24903799>
115. Zhu H, Guo S-C, Liu Z-Q, et al. Therapeutic drug monitoring of cycloserine and linezolid during anti-tuberculosis treatment in Beijing, China. *Int J Tuberc Lung Dis off J. Int Union against Tuberc Lung Dis*. 2018;22:931–936.
116. Deshpande D, Alffenaar J-WC, Köser CU, et al. d-cycloserine pharmacokinetics/pharmacodynamics, susceptibility, and dosing implications in multidrug-resistant tuberculosis: a Faustian deal. *Clin Infect Dis*. [Internet]. 2018;67:S308–S316. Available from: <https://pubmed.ncbi.nlm.nih.gov/30496460>
117. Alghamdi WA, Alsultan A, Al-Shaer MH, et al. Cycloserine population pharmacokinetics and pharmacodynamics in patients with tuberculosis. *Antimicrob Agents Chemother*. 2019;63: e00055–19.
118. van der Galiën R, Boveneind-Vrubleuskaya NV, Peloquin C, et al. Pharmacokinetic modeling, simulation, and development of a limited sampling strategy of cycloserine in patients with multidrug/extensively drug-resistant tuberculosis. *Clin Pharmacokinet*. 2020;59:899–910.
119. Hwang TJ, Wares DF, Jafarov A, et al. Safety of cycloserine and terizidone for the treatment of drug-resistant tuberculosis: a meta-analysis. *Int J Tuberc Lung Dis*. [Internet]. 2013 /June/ 03;17:1257–1266. Available from: <https://pubmed.ncbi.nlm.nih.gov/23735593>
120. Li Y, Sun F, Zhang W. Bedaquiline and delamanid in the treatment of multidrug-resistant tuberculosis: promising but challenging. *Drug Dev Res*. 2019;80:98–105. Available from: [Internet].
121. Ferlazzo G, Mohr E, Laxmeshwar C, et al. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study. *Lancet Infect Dis*. 2018;18:536–544.

122. Akkerman O, Aleksa A, Alffenaar J-W, et al. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study. *Int J Infect Dis IJID Off Publ Int Soc Infect Dis*. 2019;83:72–76.
123. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. *N Engl J Med*. 2012;366:2151–2160.
124. Kean SJ. Pretomanid: first approval. *Drugs*. 2019;79:1797–1803.
125. Winter H, Ginsberg A, Egizi E, et al. Effect of a high-calorie, high-fat meal on the bioavailability and pharmacokinetics of PA-824 in healthy adult subjects. *Antimicrob Agents Chemother*. [Internet]. 2013;57:5516 LP– 5520. Available from: <http://aac.asm.org/content/57/11/5516.abstract>
126. Dooley KE, Luetkemeyer AF, Park J-G, et al. Phase I Safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant Lopinavir-Ritonavir, Efavirenz, or Rifampin. *Antimicrob Agents Chemother*. [Internet]. 2014;58:5245 LP– 5252. Available from: <http://aac.asm.org/content/58/9/5245.abstract>
127. Winter H, Egizi E, Erondur N, et al. Evaluation of pharmacokinetic interaction between PA-824 and Midazolam in healthy adult subjects. *Antimicrob Agents Chemother*. [Internet]. 2013;57:3699 LP– 3703. Available from: <http://aac.asm.org/content/57/8/3699.abstract>
128. Sturkenboom MGG, Simbar N, Akkerman OW, et al. Amikacin dosing for MDR tuberculosis: a systematic review to establish or revise the current recommended dose for tuberculosis treatment. *Clin Infect Dis an off Publ Infect Dis Soc Am*. 2018;67:S303–S307.
129. Dijkstra JA, van Altena R, Akkerman OW, et al. Limited sampling strategies for therapeutic drug monitoring of amikacin and kanamycin in patients with multidrug-resistant tuberculosis. *Int J Antimicrob Agents*. 2015;46:332–337.
130. Smith CR, Maxwell RR, Edwards CQ, et al. Nephrotoxicity induced by gentamicin and amikacin. *Johns Hopkins Med J*. 1978;142:85–90.
131. French MA, Cerra FB, Plaut ME, et al. Amikacin and gentamicin accumulation pharmacokinetics and nephrotoxicity in critically ill patients. *Antimicrob Agents Chemother*. 1981;19:147–152.
132. van Altena R, Dijkstra JA, van der Meer ME, et al. Reduced chance of hearing loss associated with therapeutic drug monitoring of aminoglycosides in the treatment of multidrug-resistant tuberculosis. *Antimicrob Agents Chemother*. 2017 Feb 23;61(3): e01400–16.
133. Modongo C, Pasipanodya JG, Magazi BT, et al. Artificial intelligence and Amikacin exposures predictive of outcomes in multidrug-resistant tuberculosis patients. *Antimicrob Agents Chemother*. 2016;60:5928–5932.
134. Srivastava S, Modongo C, Siyambalapitiyage Dona CW, et al. Amikacin optimal exposure targets in the hollow-fiber system model of tuberculosis. *Antimicrob Agents Chemother*. 2016;60:5922–5927.
135. Peloquin CA, Berning SE, Nitta AT, et al. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. *Clin Infect Dis An Off Publ Infect Dis Soc Am*. 2004;38:1538–1544.
136. Modongo C, Pasipanodya JG, Zetola NM, et al. Amikacin concentrations predictive of ototoxicity in multidrug-resistant tuberculosis patients. *Antimicrob Agents Chemother*. 2015;59:6337–6343.
137. Ahmad N, Ahuja SD, Akkerman OW, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. *Lancet*. [Internet]. 2018;392:821–834. Available from: [https://doi.org/10.1016/S0140-6736\(18\)31644-1](https://doi.org/10.1016/S0140-6736(18)31644-1)
138. Nathanson E, Gupta R, Huamani P, et al. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. *Int J Tuberc Lung Dis*. [Internet]. 2004;8:1382–1384. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/15581210>
139. Lee HW, Kim DW, Park JH, et al. Pharmacokinetics of prothionamide in patients with multidrug-resistant tuberculosis. *Int J Tuberc Lung Dis* [Internet]. 2009;13:1161–1166. Available from: <https://pubmed.ncbi.nlm.nih.gov/19723408>.
140. Auclair B, Nix DE, Adam RD, et al. Pharmacokinetics of ethionamide administered under fasting conditions or with orange juice, food, or antacids. *Antimicrob Agents Chemother*. [Internet]. 2001;45:810–814. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/11181366>
141. Zhu M, Namdar R, Stambaugh JJ, et al. Population pharmacokinetics of ethionamide in patients with tuberculosis. *Tuberculosis (Edinb)*. [Internet]. 2002;82:91–96. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/12356460>
142. Lee SH, Seo K-A, Lee YM, et al. Low serum concentrations of moxifloxacin, prothionamide, and cycloserine on sputum conversion in multi-drug resistant TB. *Yonsei Med J*. [Internet]. 2015;56:961–967. Available from: <https://pubmed.ncbi.nlm.nih.gov/26069117>
143. Al-Shaer MH, Märtsen, A-G, Alghamdi WA, et al. Ethionamide population pharmacokinetic model and target attainment in multidrug-resistant tuberculosis. *Antimicrob Agents Chemother*. 2020.
144. WHO treatment guidelines for drug-resistant tuberculosis. 2016 Update [Internet]. 2020 Aug 20 [cited 2020 Sep 21];64(9):e00713–20. Available from: <https://apps.who.int/medicinedocs/en/m/abstract/Js23097en/>.
145. Donald PR, Diacon AH. Para-aminosalicylic acid: the return of an old friend. *Lancet Infect Dis*. [Internet]. 2015 /August/12;15:1091–1099. Available from: <https://pubmed.ncbi.nlm.nih.gov/26277036>
146. Heysell SK, Moore JL, Peloquin CA, et al. Outcomes and use of therapeutic drug monitoring in multidrug-resistant tuberculosis patients treated in Virginia, 2009–2014. *Tuberc Respir Dis (Seoul)*. [Internet]. 2015 /April/02;78:78–84. Available from: <https://pubmed.ncbi.nlm.nih.gov/25861340>
147. Peloquin CA, Berning SE, Huitt GA, et al. Once-daily and twice-daily dosing of p-aminosalicylic acid granules. *Am J Respir Crit Care Med*. 1999;159:932–934. Available from: [Internet].
148. Curry International Tuberculosis Center and California Department of Public Health. 2016. Drug-resistant tuberculosis: a survival guide for clinicians. 3rd ed. California, USA: Curry International Tuberculosis Center.
149. de Kock L, Sy SKB, Rosenkranz B, et al. Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis. *Antimicrob Agents Chemother*. 2014;58:6242–6250.
150. Deshpande D, Srivastava S, Chapagain ML, et al. The discovery of ceftazidime/avibactam as an anti-mycobacterium avium agent. *J Antimicrob Chemother*. 2017;72:i36–i42.
151. Cavanaugh JS, Jou R, Wu M-H, et al. Susceptibilities of MDR mycobacterium tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic/pharmacodynamic parameters. *J Antimicrob Chemother*. 2017;72:1678–1687.
152. Nicolau DP. Pharmacodynamic optimization of beta-lactams in the patient care setting. *Crit Care* [Internet]. 2008 /May/21;12:S2–S2. Available from: <https://pubmed.ncbi.nlm.nih.gov/18495059>
153. Wivagg CN, Bhattacharyya RP, Hung DT. Mechanisms of β -lactam killing and resistance in the context of Mycobacterium tuberculosis. *J Antibiot (Tokyo)*. 2014;67:645–654.
154. Gonzalo X, Drobniewski F. Is there a place for β -lactams in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis? Synergy between meropenem and amoxicillin/clavulanate. *J Antimicrob Chemother*. 2013;68:366–369.
155. Nicolau DP, Siew L, Armstrong J, et al. Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens. *J Antimicrob Chemother*. 2015;70:2862–2869.

156. Deshpande D, Srivastava S, Chapagain M, et al. Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis [Internet]. *Sci Adv* Available from: 2017;e1701102. Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, TX 75204, USA. <http://europepmc.org/abstract/MED/28875168>.
157. van Rijn SP, van Altena R, Akkerman OW, et al. Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis. *Eur Respir J*. [Internet]. 2016;47:1229–1234. Available from: <http://europepmc.org/abstract/MED/26743484>
158. van Rijn SP, Srivastava S, Wessels MA, et al. Sterilizing effect of Ertapenem-clavulanate in a hollow-fiber model of tuberculosis and implications on clinical dosing. *Antimicrob Agents Chemother*. 2017;61:e02039–16.
159. Zuur MA, Ghimire S, Bolhuis MS, et al. Pharmacokinetics of 2,000 Milligram ertapenem in tuberculosis patients. *Antimicrob Agents Chemother*. 2018;62:e02250–17.
160. van Rijn SP, Zuur MA, Anthony R, et al. Evaluation of Carbapenems for treatment of multi- and extensively drug-resistant mycobacterium tuberculosis. *Antimicrob Agents Chemother*. 2019;63:e01489–18.
161. Sotgiu G, D'Ambrosio L, Centis R, et al. Carbapenems to treat multidrug and extensively drug-resistant tuberculosis: a systematic review. *Int J Mol Sci*. 2016;17:373.
162. Tiberi S, Sotgiu G, D'Ambrosio L, et al. Comparison of effectiveness and safety of imipenem/clavulanate- &em>versus&em>meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB. *Eur Respir J*. [Internet]. 2016;47:1758 LP– 1766. Available from: <http://erj.ersjournals.com/content/47/6/1758.abstract>
163. Bushnell G, Stennis NL, Drobnik AM, et al. Characteristics and TB treatment outcomes in TB patients with viral hepatitis, New York City, 2000–2010. *Epidemiol Infect*. 2015;143:1972–1981.
164. Lian J, Hu P, Lu Y, et al. Prophylactic antiviral treatment reduces the incidence of liver failure among patients coinfecting with Mycobacterium tuberculosis and hepatitis B virus. *Virus Res*. 2019;270:197664.
165. Tsai M-C, Lin M-C, Hung C-H. Successful antiviral and antituberculosis treatment with pegylated interferon-alfa and ribavirin in a chronic hepatitis C patient with pulmonary tuberculosis. *J Formos Med Assoc*. 2009;108:746–750.
166. Kempker RR, Alghamdi WA, Al-Shaer MH, et al. A pharmacology perspective on simultaneous tuberculosis and Hepatitis C treatment. *Antimicrob Agents Chemother*. [Internet]. 2019;63:e01215–19. Available from: <http://aac.asm.org/content/63/12/e01215-19.abstract>
167. Yew WW, Chang KC, Chan DP, et al. Oxidative Stress and First-Line Antituberculosis Drug-Induced Hepatotoxicity. *Antimicrob Agents Chemother*. 2018 Jul 27;62(8):e02637–17.
168. Satyaraddi A, Velpandian T, Sharma SK, et al. Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity. *Int J Tuberc Lung Dis off J Int Union against Tuberc Lung Dis*. 2014;18:188–195, i–iii.
169. Svensson EM, Acharya C, Clauson B, et al. Pharmacokinetic interactions for drugs with a long half-life—evidence for the need of model-based analysis. *Aaps J*. 2016;18:171–179.
170. Svensson EM, Murray S, Karlsson MO, et al. Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug. *J Antimicrob Chemother*. 2015;70:1106–1114.
171. Guaiastrenne B, Ramachandran G, Karlsson MO, et al. Suboptimal antituberculosis drug concentrations and outcomes in small and HIV-coinfecting children in India: recommendations for dose modifications. *Clin Pharmacol Ther*. 2018;104:733–741.
172. Esposito S, Codecasa LR, Centis R. The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection. *Eur Respir J*. [Internet]. 2015;45:571 LP– 574. Available from: <http://erj.ersjournals.com/content/45/2/571.abstract>
173. Liverpool U of. HIV drug interactions [Internet]. [cited 2020 Sep 21]. Available from: <https://www.hiv-druginteractions.org/checker>.
174. Daskapan A, Idrus LR, Postma MJ, et al. A systematic review on the effect of HIV infection on the pharmacokinetics of first-line tuberculosis drugs. *Clin Pharmacokinet*. [Internet]. 2019;58:747–766. Available from: <https://pubmed.ncbi.nlm.nih.gov/30406475>
175. Saito N, Yoshii Y, Kaneko Y, et al. Impact of renal function-based anti-tuberculosis drug dosage adjustment on efficacy and safety outcomes in pulmonary tuberculosis complicated with chronic kidney disease. *BMC Infect Dis*. 2019;19:374.
176. Pazhayattil GS, Shirali AC. Drug-induced impairment of renal function. [Internet]. *Int J Nephrol Renovasc Dis*. 2014;7:457–468. Available from: <https://pubmed.ncbi.nlm.nih.gov/25540591>
177. Milburn H, Ashman N, Davies P, et al. Guidelines for the prevention and management of &em>Mycobacterium tuberculosis&em> infection and disease in adult patients with chronic kidney disease. *Thorax*. [Internet]. 2010;65:559 LP– 570. Available from: <http://thorax.bmj.com/content/65/6/559.abstract>
178. Slocum JL, Heung M, Pennathur S. Marking renal injury: can we move beyond serum creatinine? [Internet]. *Transl Res*. 2012;159:277–289. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3308350/>
179. Roberts DM, Sevastos J, Carland JE, et al. Clinical pharmacokinetics in kidney disease: application to rational design of dosing regimens. *Clin J Am Soc Nephrol*. [Internet]. 2018 /July/ 24;13:1254–1263. Available from: <https://pubmed.ncbi.nlm.nih.gov/30042221>
180. Chew R, Jongbloed S, Jegatheesan D, et al. Ethambutol is cleared by a contemporary high-flux hemodialyzer, and drug monitoring ensures safety and therapeutic effect. *Antimicrob Agents Chemother*. 2017;61:e01988–16.
181. Strunk A-K, Ciesek S, Schmidt JJ, et al. Single- and multiple-dose pharmacokinetics of ethambutol and rifampicin in a tuberculosis patient with acute respiratory distress syndrome undergoing extended daily dialysis and ECMO treatment. *Int J Infect Dis IJID Off Publ Int Soc Infect Dis*. 2016;42:1–3.
182. Batchelor HK, Marriott JF. Paediatric pharmacokinetics: key considerations. [Internet]. *Br J Clin Pharmacol*. 2015;79:395–404. Available from: <https://pubmed.ncbi.nlm.nih.gov/25855821>
183. Martial LC, Kerkhoff J, Martinez N, et al. Evaluation of dried blood spot sampling for pharmacokinetic research and therapeutic drug monitoring of anti-tuberculosis drugs in children. *Int J Antimicrob Agents*. 2018;52:109–113.
184. Gafar F, Arifin H, Jurnal YD, et al. Antituberculosis drug-induced liver injury in children: incidence and risk factors during the two-month intensive phase of therapy. *Pediatr Infect Dis J*. 2019;38:50–53.
185. Swaminathan S, Pasipanodya JG, Ramachandran G, et al. Drug concentration thresholds predictive of therapy failure and death in children with tuberculosis: bread crumb trails in random forests. *Clin Infect Dis an off Publ Infect Dis Soc Am*. 2016;63:S63–S74.
186. O'Kelly B, Murtagh R, Lambert JS. Therapeutic drug monitoring of HIV antiretroviral drugs in pregnancy: a narrative review. *Ther Drug Monit*. 2020;42:229–244.
187. Abdelwahab MT, Leisegang R, Dooley KE, et al. Population pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in pregnant South African women with tuberculosis and HIV. *Antimicrob Agents Chemother*. 2020;64:e01978–19.
188. Denti P, Martinson N, Cohn S, et al. Population pharmacokinetics of rifampin in pregnant women with tuberculosis and HIV coinfection in Soweto, South Africa. *Antimicrob Agents Chemother*. 2015;60:1234–1241.
189. Van Kampenhout E, Bolhuis MS, Alffenaar J-WC, et al. Pharmacokinetics of moxifloxacin and linezolid during and after pregnancy in a patient with multidrug-resistant tuberculosis. *Eur Respir J*. [Internet]. 2017;49:1601724. Available from: <http://erj.ersjournals.com/content/49/3/1601724.abstract>
190. Gupta A, Mathad JS, Abdel-Rahman SM, et al. Toward earlier inclusion of pregnant and postpartum women in tuberculosis drug trials: consensus statements from an

- international expert panel. *Clin Infect Dis.* [Internet]. 2015;62:761–769.
191. Ebers A, Stroup S, Mpagama S, et al. Determination of plasma concentrations of levofloxacin by high performance liquid chromatography for use at a multidrug-resistant tuberculosis hospital in Tanzania. *PLoS One.* 2017;12:e0170663.
192. Kim HY, Heysell SK, Mpagama S, et al. Challenging the management of drug-resistant tuberculosis. *Lancet.* England. 2020 Mar 7;395(10226):783.
193. Alffenaar J-WC, Heysell SK, Mpagama SG. Therapeutic drug monitoring: the need for practical guidance. *Clin Infect Dis.* [Internet]. 2019;68:1065–1066.